Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: Data from the NIH HBV OLT study

Clinical Transplantation

Volumn 25, Issue 2, 2011, Pages

  Han, Steven Huy ^a   Reddy, K Rajender ^b   Keeffe, Emmet B ^c   Soldevila Pico, Consuelo ^d   Gish, Robert ^e   Chung, Raymond T ^f   Degertekin, Bulent ^g   Lok, Anna ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Hepatitis B virus; Liver cancer; Predictors; Recurrence; Risk factors

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE DURATION; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT INDICATION;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953331013     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01349.x     Document Type: Article

References (32)

1. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006: 13: 787.
2. Organ Procurement and Transplantation Network. 2009., Health Resources and Services Administration. Ref Type: Computer Program.
3. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693.
4. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001: 33: 464.
5. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006: 354: 1011.
6. Chang TT, Gish RG, De Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006: 354: 1001.
7. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008: 359: 2442-55.
8. Kim WR, Terrault NA, Pedersen RA et al. Trends in waiting list registration for liver transplantation for virol hepatitis in the United States. Gastroenterology 2009: 137: 1680.
9. Faria LC, Gigou M, Roque-Afonso AM et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008: 134: 1890.
10. Kiyici M, Yilmaz M, Akyildiz M et al. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc 2008: 40: 1511.
11. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007: 39: 3276.
12. Wong SN, Reddy KR, Keeffe EB et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007: 13: 334.
13. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001: 33: 1394.
14. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004: 351: 1521.
15. Fontana RJ, Keeffe EB, Carey W et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002: 8: 433.
16. Schiff E, Lai CL, Hadziyannis S et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007: 13: 349.
17. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003: 37: 429.
18. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004: 127: S179.
19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005: 42: 1208.
20. Zheng SS, Xu X, Wu J et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008: 85: 1726.
21. Xu X, Ke QH, Shao ZX et al. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci 2009: 54: 385.
22. Zou WL, Zang YJ, Chen XG, Shen ZY. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation. Hepatobiliary Pancreat Dis Int 2008: 7: 145.
23. Han K, Tzimas GN, Barkun JS et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol. 2007: 21: 39.
24. Yang SH, Suh KS, Lee HW et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007: 141: 598.
25. Andorno E, Salizzoni M, Schieroni R, De Hemptinne B. Role of serum alpha-fetoprotein in pre- and post-orthotopic liver transplantation (OLT) for malignant disease. J Nucl Med Allied Sci 1989: 33: 132.
26. Chuma M, Hige S, Kamiyama T et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009: 44: 991.
27. Kim BK, Park JY, Kim DY et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008: 28: 393.
28. Schlitt HJ, Neipp M, Weimann A et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999: 17: 324.
29. Regalia E, Fassati LR, Valente U et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998: 5: 29.
30. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001: 233: 652.
31. Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg 2002: 26: 257.
32. Zavaglia C, De Carlis L, Alberti AB et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005: 100: 2708.